BusinessGBT Receives FDA Breakthrough Therapy Designation for Voxelotor for Treatment of Sickle Cell Disease (SCD)By Nasdaq OMXJan 9, 2018, 1:00 PM UTC
BusinessGlobal Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell DiseaseBy Nasdaq OMXNov 13, 2017, 1:00 PM UTC
BusinessSickle Cell Disease Treatment Market to Reach US$ 584.0 Mn by 2025 – Persistence Market ResearchBy Nasdaq OMXSep 26, 2017, 3:18 PM UTC
